Address
Email address
Phone number
Website
Celvia ehk endine Tervisetehnoloogiate Arenduskeskus on ühenduslüli alusuuringute ja meditsiini vahel. Loe meie kohta täpsemalt.
Name
Celvia CC AS
Registry code
11673707
VAT number
EE101318989
Type
AS - Joint Stock Company
Status
Registered
Foundation date
12.08.2009 (15)
Financial year
01.01-31.12
Capital
25 756.00 €
Activity
86902 - Activities of medical laboratories, blood banks, sperm banks and other similar banks 72111 - Research and experimental development on biotechnology
-
-
-
-
-
-
-
No tax arrears
-
-
Owner | Representative | Beneficial owner | Roles | |
---|---|---|---|---|
Kaarel Krjutškov
| 31% - 7 924.92 EUR | Board member | - | Shareholder |
Andres Salumets
| 46% - 11 887.38 EUR | Board member | - | Shareholder |
Ari Pekka Kalevi Sillanaukee
| - | - | - | Board member |
Jaanus Pikani
| - | - | - | Board member |
Ülle Jaakma
| - | - | - | Board member |
EESTI TÕULOOMAKASVATAJATE ÜHISTU 10064515 | - | - | - | Founder |
Aktsiaselts Nova Vita Kliinik 10285009 | - | - | - | Founder |
AS Viimsi Haigla 10391415 | - | - | - | Founder |
aktsiaselts Biotehnoloogia Park Kinnisvara 10834232 | - | - | - | Founder |
Bestenbalt OÜ 10874510 | - | - | - | Founder |
AS Kliinik Elite 10911961 | - | - | - | Founder |
osaühing TBD Pharmatech 11204964 | - | - | - | Founder |
Tallinna Ülikool 74000122 | - | - | - | Founder |
Tartu Ülikool 74001073 | - | - | - | Founder |
Eesti Maaülikool 74001086 | - | - | - | Founder |
Owner | Representative | Beneficial owner | Roles | |
---|---|---|---|---|
Sen-Lab OÜ 14528578 | - | - | - | Founder |
Turnover | State taxes | Labor taxes and payments | Employees | |
---|---|---|---|---|
2024 Q4 | 272 193.72 € | 131 031.96 € | 135 222.28 € | 44 |
2024 Q3 | 139 659.16 € | 130 735.83 € | 138 834.1 € | 41 |
2024 Q2 | 156 223.83 € | 139 691.38 € | 133 417.31 € | 44 |
2024 Q1 | 178 384.32 € | 135 358 € | 145 705.34 € | 44 |
2023 Q4 | 240 772.54 € | 139 604.97 € | 141 282.73 € | 44 |
2023 Q3 | 346 138.66 € | 118 221.75 € | 127 617.92 € | 51 |
2023 Q2 | 268 416.93 € | 120 363.05 € | 115 391.95 € | 56 |
2023 Q1 | 157 714.03 € | 103 158.15 € | 110 731.75 € | 51 |
2022 Q4 | 161 378.31 € | 99 827.83 € | 94 760.65 € | 45 |
2022 Q3 | 76 321.6 € | 90 695.12 € | 96 014.09 € | 39 |
2022 Q2 | 201 412.77 € | 92 431.29 € | 85 375.79 € | 46 |
2022 Q1 | 110 461.07 € | 111 183.52 € | 119 015.93 € | 48 |
2021 Q4 | 196 247.17 € | 101 646.81 € | 88 919.86 € | 47 |
2021 Q3 | 71 992.45 € | 87 228.92 € | 90 559.28 € | 48 |
2021 Q2 | 207 354.17 € | 109 138.04 € | 101 118.29 € | 45 |
2021 Q1 | 341 674.16 € | 101 920.71 € | 98 064.26 € | 48 |
2020 Q4 | 186 277.5 € | 87 323.83 € | 81 961.78 € | 51 |
2020 Q3 | 140 736.46 € | 80 829.01 € | 76 358.75 € | 47 |
2020 Q2 | 260 107.97 € | 93 315.56 € | 71 889.24 € | 38 |
2020 Q1 | 96 815.49 € | 62 106.76 € | 62 242.83 € | 35 |